Real-world data reveals how often breast cancer patients get PIK3CA testing and alpelisib

A new study documents actual clinical practice patterns for a targeted cancer treatment that depends on genetic testing. The findings could help oncology practices, pharmaceutical companies, and payers understand whether patients are receiving precision medicine as intended—or whether barriers exist that limit access to this therapy.

Originaltitel: PIK3CA mutation testing and alpelisib use in metastatic breast cancer: a real-world data set